FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097662298> ?p ?o ?g. }

• W2097662298 abstract "Patients with Down's syndrome and shunt lesions are at high risk of developing pulmonary arterial hypertension (PAH) earlier than patients without Down's syndrome. However, data on the efficacy of PAH-specific therapy in patients with Down's syndrome are limited. The aim of this retrospective analysis was to determine the long-term efficacy of the dual endothelin receptor antagonist, bosentan, in Eisenmenger's syndrome (ES) patients with Down's syndrome.In this observational study adults with Down's syndrome with a confirmed diagnosis of ES (World Health Organization functional class III) and receiving bosentan therapy and were followed up long term. Clinical evaluation at baseline and follow-up visits included resting transcutaneous arterial oxygen saturation and laboratory assessments. Exercise capacity was evaluated using a 6-minute walk test where transcutaneous arterial oxygen saturation at peak exercise (SpO2), 6-minute walk distance (6MWD) and Borg dyspnoea index were assessed. A full echocardiographic assessment was conducted at baseline and follow-up visits.Overall, seven adults (mean age 29.6 ± 11.2 years; 57% male) received bosentan at a starting dose of 62.5 mg twice daily. This was increased to the target dose of 125 mg twice daily 4 weeks later. All patients remained on bosentan until the end of the study. After a mean (± standard deviation) duration of 52.2 ± 3.9 months (range: 46.0-55.5 months), 6MWD had increased from 199.6 ± 69.1 metres to 303.7 ± 99.9 metres (P < 0.05) and SpO2 at the end of the 6-minute walk test had increased from 61.6 ± 7.6% to 74.7 ± 6.2% (P < 0.05). Echocardiography demonstrated a significant change in acceleration time from 62.9 ± 11.6 m/s to 83.0 ± 9.6 m/s (P = 0.0156), and acceleration time/ejection time ratio from the pulmonary flow from 0.24 ± 0.04 at baseline to 0.30 ± 0.02 (P = 0.0156) at final follow-up.Long-term treatment with bosentan significantly improved exercise capacity and oxygen saturation following exercise in adult ES patients with Down's syndrome. These data confirm that the presence of Down's syndrome does not affect the response to oral bosentan therapy." @default.
• W2097662298 created "2016-06-24" @default.
• W2097662298 creator A5043903341 @default.
• W2097662298 creator A5058260731 @default.
• W2097662298 creator A5085532484 @default.
• W2097662298 creator A5088289616 @default.
• W2097662298 date "2013-09-18" @default.
• W2097662298 modified "2023-09-30" @default.
• W2097662298 title "Long-term results of treatment with bosentan in adult Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart disease" @default.
• W2097662298 cites W1595082333 @default.
• W2097662298 cites W1967759817 @default.
• W2097662298 cites W1967779144 @default.
• W2097662298 cites W1974206711 @default.
• W2097662298 cites W1985089277 @default.
• W2097662298 cites W1987388573 @default.
• W2097662298 cites W1992379518 @default.
• W2097662298 cites W1992914659 @default.
• W2097662298 cites W1996765504 @default.
• W2097662298 cites W2002114847 @default.
• W2097662298 cites W2003275918 @default.
• W2097662298 cites W2006822727 @default.
• W2097662298 cites W2007625591 @default.
• W2097662298 cites W2020212205 @default.
• W2097662298 cites W2020973304 @default.
• W2097662298 cites W2043119504 @default.
• W2097662298 cites W2078897386 @default.
• W2097662298 cites W2085392953 @default.
• W2097662298 cites W2095512932 @default.
• W2097662298 cites W2096962305 @default.
• W2097662298 cites W2097141247 @default.
• W2097662298 cites W2100196311 @default.
• W2097662298 cites W2102144395 @default.
• W2097662298 cites W2107432762 @default.
• W2097662298 cites W2121538692 @default.
• W2097662298 cites W2126738653 @default.
• W2097662298 cites W2127994875 @default.
• W2097662298 cites W2130754007 @default.
• W2097662298 cites W2136055413 @default.
• W2097662298 cites W2152998682 @default.
• W2097662298 cites W2163094503 @default.
• W2097662298 cites W2169989281 @default.
• W2097662298 cites W2486330806 @default.
• W2097662298 cites W4388839 @default.
• W2097662298 doi "https://doi.org/10.1186/1471-2261-13-74" @default.
• W2097662298 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3848635" @default.
• W2097662298 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24047157" @default.
• W2097662298 hasPublicationYear "2013" @default.
• W2097662298 type Work @default.
• W2097662298 sameAs 2097662298 @default.
• W2097662298 citedByCount "29" @default.
• W2097662298 countsByYear W20976622982014 @default.
• W2097662298 countsByYear W20976622982015 @default.
• W2097662298 countsByYear W20976622982016 @default.
• W2097662298 countsByYear W20976622982017 @default.
• W2097662298 countsByYear W20976622982018 @default.
• W2097662298 countsByYear W20976622982019 @default.
• W2097662298 countsByYear W20976622982020 @default.
• W2097662298 countsByYear W20976622982021 @default.
• W2097662298 countsByYear W20976622982022 @default.
• W2097662298 countsByYear W20976622982023 @default.
• W2097662298 crossrefType "journal-article" @default.
• W2097662298 hasAuthorship W2097662298A5043903341 @default.
• W2097662298 hasAuthorship W2097662298A5058260731 @default.
• W2097662298 hasAuthorship W2097662298A5085532484 @default.
• W2097662298 hasAuthorship W2097662298A5088289616 @default.
• W2097662298 hasBestOaLocation W20976622981 @default.
• W2097662298 hasConcept C118552586 @default.
• W2097662298 hasConcept C126322002 @default.
• W2097662298 hasConcept C141071460 @default.
• W2097662298 hasConcept C144980905 @default.
• W2097662298 hasConcept C164705383 @default.
• W2097662298 hasConcept C170493617 @default.
• W2097662298 hasConcept C2776345702 @default.
• W2097662298 hasConcept C2779249879 @default.
• W2097662298 hasConcept C2779954681 @default.
• W2097662298 hasConcept C2780074459 @default.
• W2097662298 hasConcept C2781109936 @default.
• W2097662298 hasConcept C555175668 @default.
• W2097662298 hasConcept C71924100 @default.
• W2097662298 hasConceptScore W2097662298C118552586 @default.
• W2097662298 hasConceptScore W2097662298C126322002 @default.
• W2097662298 hasConceptScore W2097662298C141071460 @default.
• W2097662298 hasConceptScore W2097662298C144980905 @default.
• W2097662298 hasConceptScore W2097662298C164705383 @default.
• W2097662298 hasConceptScore W2097662298C170493617 @default.
• W2097662298 hasConceptScore W2097662298C2776345702 @default.
• W2097662298 hasConceptScore W2097662298C2779249879 @default.
• W2097662298 hasConceptScore W2097662298C2779954681 @default.
• W2097662298 hasConceptScore W2097662298C2780074459 @default.
• W2097662298 hasConceptScore W2097662298C2781109936 @default.
• W2097662298 hasConceptScore W2097662298C555175668 @default.
• W2097662298 hasConceptScore W2097662298C71924100 @default.
• W2097662298 hasIssue "1" @default.
• W2097662298 hasLocation W20976622981 @default.
• W2097662298 hasLocation W20976622982 @default.
• W2097662298 hasLocation W20976622983 @default.
• W2097662298 hasLocation W20976622984 @default.
• W2097662298 hasOpenAccess W2097662298 @default.
• W2097662298 hasPrimaryLocation W20976622981 @default.
• W2097662298 hasRelatedWork W2047229386 @default.

• next